Progressive vision loss is a major complication for many diabetics. Until now, patients had to wait until the condition has become severe to receive either monthly eye injections or implants to ameliorate some of the symptoms. Significant risks of these injections and implants include cataracts, inflammation, infection, and increased intraocular pressure. And 50% of patients see no improvement from these treatments.
Verseon is advancing the first and only oral prophylactic treatment candidates for this form of vision loss. Oral administration eliminates the risks that make other treatments unsuitable for prophylaxis. They are safe for preventative use before the first signs of retinal change occur.
Diabetics suffering from diabetic retinopathy who are threatened with vision loss
Estimated global market for prevention of diabetes-related vision loss